& The Motley Fool
Hello, 360!
Check out some of our top movers for today. Stay ahead as the most prepared trader on the Street!
Alert:
Grab JW’s upcoming FOUR picks of the Week for only $29.
Offer Ends Soon…
 |
FOCUS LIST🔎
TRAW – Surged over 100% in pre-market after reporting advancements in developing Tivoxavir Marboxil for H5N1 Bird Flu.
RAPT – Climbed over 40% in pre-market after announcing an exclusive licensing deal with Shanghai Jemincare Pharmaceutical for a novel long-acting anti-IgE antibody.
PRZO – Increased over 20% in pre-market after revealing a significant Australian order for drone safety systems, reinforcing its industry leadership.
*Sponsored by CompareCredit
2 Cards Offering 0% Interest Until 2026
Managing credit card debt can be challenging due to high-interest charges. These cards let you avoid interest fees for up to 18 months.
Discover more.
HOTLIST🔥
TRAW – Up over 100% in pre-market following the announcement of progress with Tivoxavir Marboxil for H5N1 Bird Flu.
Traws Pharma Inc. (TRAW) specializes in developing small molecule oral therapies for respiratory viral diseases and cancer.
In pre-market trading, the company revealed extensive progress in its investigational therapy for treating H5N1 bird flu.
Noteworthy points include:
Investigational treatment for H5N1 Bird Flu.
Phase 1 dosing successfully completed in healthy volunteers.
Significant inhibition of drug-resistant and bird flu strains observed in vitro.
In vivo studies in mice demonstrate significant protection against H5N1 virus replication.
Following these updates, TRAW shares increased by over 100% in pre-market.
The $9.70 mark served as support in pre-market and is a critical watch point.
Targets above this are set at $10.70, $12.20, $13.50, with the pre-market high at $15.89.
Below $9.70, key support levels to monitor are $9, $8, $7.50, $6, and a gap fill at $5.02.
RAPT – Increased over 40% in pre-market following the announcement of an exclusive licensing agreement with Shanghai Jemincare Pharmaceutical for a new long-acting anti-IgE antibody.
RAPT Therapeutics Inc. (RAPT) focuses on developing oral small molecule therapies for oncology and inflammatory diseases.
This morning, RAPT announced it has entered an exclusive licensing agreement for JYB1904, a clinical-stage, extended half-life anti-IgE monoclonal antibody.
Transaction highlights include:
– RAPT gains global rights excluding China.
– Jemincare receives $35 million upfront and additional milestone payments up to $672.5 million, along with royalties on future sales.
– Jemincare is conducting Phase 2 trials for asthma and chronic urticaria in China.
As a result, shares of RAPT rose over 40% in pre-market.
The $1.40 threshold acted as resistance in the pre-market and is crucial to monitor.
Above this level, watch for targets at $1.60, $1.75, and then the pre-market high at $1.97.
If prices fall below $1.40, key levels are $1.26, $1.16, $1, with a gap fill at $0.8254.
*Sponsored by The Motley Fool
Smart Money, Smart Machines
Described as “the rocket fuel of AI” by Wired, this innovation is causing a significant stir on Wall Street. Projections reaching $80 trillion – equivalent to 41 Amazons – signal immense potential. Sharp investors can take advantage of this technology that seems poised for dominance. Thanks to The Motley Fool, you can access the complete story in this exclusive report.
Unlock the secrets of tomorrow’s tech revolution today.
PRZO – Rose over 20% in pre-market after announcing its major Australian order for drone safety systems, enhancing its industry position.
ParaZero Technologies Ltd. (PRZO) specializes in designing and selling autonomous parachute safety systems for commercial drones globally.
Today, the company released a press announcement regarding its earlier secured order for SafeAir™ systems from a key distributor focusing on drones and their technology in Australia.
This order showcases ParaZero’s growth in Australia’s drone sector, driven by regulatory approvals and strategic partnerships. As drone usage expands across industries, ParaZero’s advanced solutions represent their commitment to establishing safety standards while promoting innovation.
Shares of PRZO increased by over 20% in pre-market following the announcement.
The $1.93 price point served as support in pre-market and is critical to monitor.
Targets above are set at $2.05, $2.20, $2.30, and then the pre-market high at $2.36. Watch for $2.44 and $2.77 beyond that.
If the price drops below $1.93, a gap to fill arises at $1.76, followed by $1.53.
MARKET NEWS📰
DISCLAIMER
: For a comprehensive understanding of any Ragingbull.com, LLC (“RagingBull”) subscription or service (“Services”), please read our full disclaimer available at
https://ragingbull.com/disclaimer
FOR EDUCATIONAL AND INFORMATIONAL USE ONLY; NOT INVESTMENT ADVICE.
RagingBull Services provided are solely for educational purposes and should not be interpreted as a securities-related offer or solicitation, nor should they be considered personalized investment advice. We advise consulting a licensed or registered professional before making any investment decisions.
RESULTS SHOWN ARE NOT TYPICAL NOR VERIFIED.
Past trading performance of RagingBull owners or employees, including testimonials from non-employees that may depict profitability, have not been verified and results are not necessarily indicative of future performance. Actual trading results can vary due to multiple factors such as experience, risk management practices, market conditions, and invested capital. Investing in securities involves risk; you may lose some, all, or possibly more than your initial investment.
RAGINGBULL DOES NOT ACT AS AN INVESTMENT ADVISOR OR REGISTERED BROKER.
Neither RagingBull nor its owners or employees are registered as a broker-dealer, investment advisor, or IA representative with the U.S. Securities and Exchange Commission or any state regulatory authority. Employees, owners, and service providers of RagingBull.com might receive compensation based on services sold to subscribers.
RagingBull.com, LLC may recover legal fees and costs.
In case any lawsuit or action arises due to transactions with RagingBull.com, LLC or its affiliates or to enforce or explain these Terms of Service, RagingBull.com is entitled to recover attorneys’ fees and costs along with any other relief to which it may be entitled.
*Sponsored Content:
If you purchase products through links in this email, you should assume we have an affiliate connection with the company providing those products and may receive payment. Please conduct your own independent research before making any purchases. We recommend companies we partner with, but only spend money on products or services when you believe they will meet your needs.
WE MAY HOLD SECURITIES DISCUSSED.
RagingBull has not received compensation from any security issuer mentioned except possibly from advertisers. Nonetheless, Ragingbull.com LLC and its affiliates might buy, sell, or hold positions, either long or short, in the securities of companies discussed in this communication.
